Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%

EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24

Wanbury Ltd, a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced Q2 FY25 revenue from operations stood at Rs. 161.2 crore, an increase of 11.6% Y-o-Y driven by sales volume growth in key products like Metformin and Sertraline in API business and sales growth in Branded Formulation business.

EBITDA Margins for Q2 FY25 stood at 13.4%. EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24, a growth of 19.6% mainly on account of sales volume growth in key products like Metformin and Sertraline in API business and sales growth in Branded Formulation business.

For the third consecutive year, Wanbury's API manufacturing site in Patalganga won two safety awards at the Maharashtra Safety Awards Competition 2023, organized by the Maharashtra State Government, upholding its commitment to the highest safety standards. The facility has also received a USFDA Establishment Inspection Report (EIR) with a No Action Indicated (NAI) designation and zero 483 observations, confirming full compliance with regulatory standards.

Commenting on the performance, Mohan Rayana, Director, Wanbury Ltd. said, "Our quarterly performance demonstrates steady year-on-year growth, with revenue rising by 11.6% at Rs. 161 crore and EBITDA by 19.6% at Rs. 21.6 crore, driven by increased sales volumes in key API products such as Metformin and Sertraline, as well as growth in the Branded Formulation segment."

"We continue to enhance our current API products by expanding capacity and geographic reach, with plans to accelerate growth by launching 3 new APis in the near term. The Tanuku facility is currently undergoing a temporan1 shutdown for upgrades and further capacity expansion which will be completed shortly, allowing full operations to resume with improved productivity and cost efficiency from December 2024 onwards. Additionally, obtaining the Certificate of Suitability (CEP) for Dextromethorphan API from the European Directorate for the Quality of Medicines (EDQM) paves way for expansion into the European market. Our commitment to safety and quality has been acknowledged with the Patalganga site receiving two safety awards for the third consecutive year," added Rayana.

In Q3 FY25, the focus area of the company is cost improvement through process engineering and it will continue to support the margin improvement.